These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39241296)

  • 21. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
    Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
    Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer.
    Gao M; Zhang X; Yan H; Sun D; Yang X; Yuan F; Ju Y; Wang L; Wang J; Zhao W; Zhang D; Li L; Xu X; Ma J; Hu Y; Zhang X
    Support Care Cancer; 2023 Nov; 31(12):671. PubMed ID: 37924363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Selpercatinib in
    Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
    N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
    Saleh K; Khalife N; Felefly T
    Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417
    [No Abstract]   [Full Text] [Related]  

  • 26. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
    Ali F; Neha K; Chauhan G
    Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Locally Advanced NSCLC Patient Harboring a Rare KIF13A-RET Fusion Benefited from Pralsetinib: A Case Report.
    Chang Z; Zhu T; Jiang H; Ou W; Wang S
    Curr Oncol; 2024 Jun; 31(7):3808-3814. PubMed ID: 39057153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
    Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
    Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China.
    Lu S; Shen L; Wang Q; Chen H; Zhao Y; Li Y; Segall G; Khanal M; Zhang X; Ding D; Shao J; Pang L
    Adv Ther; 2024 Nov; 41(11):4248-4265. PubMed ID: 39316291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selpercatinib in Patients With
    Drilon A; Subbiah V; Gautschi O; Tomasini P; de Braud F; Solomon BJ; Shao-Weng Tan D; Alonso G; Wolf J; Park K; Goto K; Soldatenkova V; Szymczak S; Barker SS; Puri T; Bence Lin A; Loong H; Besse B
    J Clin Oncol; 2023 Jan; 41(2):385-394. PubMed ID: 36122315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
    Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
    Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
    Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients.
    Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
    Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
    Gu L; Ji W; Xu Y; Han Y; Jian H
    Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pralsetinib for the treatment of non-small cell lung cancer.
    Fu XY; Dong XD; Zeng L; Ashby CR; Chen ZS; Cheng C
    Drugs Today (Barc); 2021 Sep; 57(9):559-569. PubMed ID: 34586104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
    Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
    Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
    Gazeu A; Aubert M; Pissaloux D; Lantuejoul S; Pérol M; Ikhlef N; Bouhamama A; Franceschi T; Swalduz A
    Clin Lung Cancer; 2023 Jan; 24(1):72-75. PubMed ID: 36437214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.